Protean BioDiagnostics to Present at AACR 2021 Annual Meeting
ORLANDO (March 17, 2021) – Protean BioDiagnostics Inc. (“Protean”), a disruptive biotechnology company developing and commercializing novel cancer diagnostics supporting precision oncology, is pleased to announce that its below-referenced abstract has been accepted for presentation at the upcoming American Association for Cancer Research (AACR) Virtual Annual Meeting, April 10-15 and May 17-21, 2021.
“Targeted therapy for breast cancer requires a better understanding of the role of tumor driving signaling pathways,” said Dr. Anthony Magliocco, President and CEO of Protean. “Leveraging Philips’ OncoSignal technology we show evidence that using certain signaling pathway assays may provide a superior approach to current immunohistochemistry methods to more effectively select patients for specific precision oncology targeted therapy treatments.”
Philips’ OncoSignal technology has been used to profile the activity of cell signaling pathways in different breast cancer subtypes, leading to a better understanding of what drives tumor growth in these subtypes.
Abstract Title: Breast cancer IHC subtypes display heterogenous and independent targetable signaling pathway activity profiles
Session Type: E-Poster Session
Session Category: Clinical Research (Excluding Trials)
Session Title: Laboratory Correlates for Targeted Agents
Permanent Abstract Number: 533
About Protean BioDiagnostics
Protean BioDiagnostics is revolutionizing modern healthcare with our Protean MAPS™ system, which integrates health screening, diagnostics, treatment guidance, and tele-medicine backed decision support.
We collaborate with physicians and health groups to support them in providing the best possible care for their patients, regardless of where they live.